(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 1 598 419 A1

(12) EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:
23.11.2005 Bulletin 2005/47

(21) Application number: **04715540.3**

(22) Date of filing: **27.02.2004**

(51) Int Cl.[7]: **C12N 15/00**, C07K 16/32, C12N 5/00, C12P 21/08, A61K 39/395, A61K 9/127, A61P 35/00, G01N 33/574

(86) International application number:
PCT/JP2004/002402

(87) International publication number:
WO 2004/076658 (10.09.2004 Gazette 2004/37)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: **28.02.2003 JP 2003054670**
09.07.2003 JP 2003194643

(71) Applicants:
- **Mitsubishi Pharma Corporation**
  Osaka-shi, Osaka 541-0046 (JP)
- **Keio University**
  Tokyo 108-0073 (JP)

(72) Inventors:
- **HOSOKAWA, Saiko,**
  c/o Mitsubishi Pharma Corporation
  Tokyo 1038405 (JP)
- **AOKI, Masahiko, School Of Medicine, Keio Univ.**
  Tokyo 1608582 (JP)
- **HIRAKAWA, Yoko,**
  c/o Mitsubishi Pharma Corporation
  Tokyo 1038405 (JP)
- **ITAMI, Seima,**
  c/o Mitsubishi Pharma Corporation
  Tokyo 1038405 (JP)
- **UMEKI, Hiroe,**
  c/o Mitsubishi Pharma Corporation
  Tokyo 1038405 (JP)
- **SAIKAWA, Yoshiro,**
  School Of Medicine, Keio Univ.
  Tokyo 1608582 (JP)
- **KUMAI, Koichiro, School Of Medicine, Keio Univ.**
  Tokyo 1608582 (JP)
- **FUKUDA, Kazumasa,**
  School Of Medicine, Keio Univ.
  Tokyo 1608582 (JP)

(74) Representative: **von Kreisler Selting Werner**
Patentanwälte
P.O. Box 10 22 41
50462 Köln (DE)

(54) MONOCLONAL ANTIBODY, GENE ENCODING THE SAME, HYBRIDOMA, MEDICINAL COMPOSITION AND DIAGNOSTIC REAGENT

(57) A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by using the antibody alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein. More specifically, an anti-cancer drug is obtained by using an antibody, in which variable region of its heavy chain comprises the amino acid sequence of SEQ ID NO: 115 and variable region of the light chain comprises the amino acid sequence of SEQ ID NO: 117, alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein.



Fig. 2

EP 1 598 419 A1